Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1153-1158

  Aeschlimann, Jeffrey R ^a,b,d   Hershberger, Ellie ^a,b   Rybak, Michael J ^a,b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; SULBACTAM; TROVAFLOXACIN; VANCOMYCIN;

ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BACTERIUM ISOLATION; DOSE RESPONSE; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROTEIN BINDING; RELIABILITY; STATISTICAL ANALYSIS;

AMPICILLIN; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; STAPHYLOCOCCUS AUREUS; SULBACTAM; VANCOMYCIN RESISTANCE;

EID: 0034058282     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1153-1158.2000     Document Type: Article

References (33)

1. Aeschlimann, J. R., E. Hershberger, and M. J. Rybak. 1999. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1914-1918.
2. Asada, K., Y. Inaba, E. Tateda-Suzuki, K. Kuwahara-Arai, T. Ito, and K. Hiramatsu. 1995. Evolution and resistance expression of MRSA. Evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. Acta Biochim. Pol. 42:517-524.
3. Biavasco, F., E. Giovanetti, M. P. Montanari, R. Lupidi, and P. Varaldo. 1991. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J. Antimicrob. Chemother. 27: 71-79.
4. Billot-Klein, D., L. Gutman, D. Bryant, D. Bell, J. van Heijenoort, J. Grewal, and D. Shlaes. 1996. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. J. Bacteriol. 178:4696-4703.
5. Blaser, J. 1985. In vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
6. +-dependent D-lactate dehydrogenase and insertional inactivation in a glycopeptide-resistant isolate. J. Bacteriol. 179:6756-6763.
7. Cappeletty, D. M., S. L. Kang, S. M. Palmer, and M. J. Rybak. 1995. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob. Agents Chemother. 33:1797-1801.
8. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:813-815.
9. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 44:765-766.
10. Centers for Disease Control and Prevention. 1997. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. Morbid. Mortal. Weekly Rep. 46:624-635.
11. Cunha, B. A., S. M. Hussain Qadri, Y. Ueno, E. A. Walters, and P. Domenico. 1998. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J. Antimicrob. Chemother. 39: 29-34.
12. Daum, R. S., S. Gupta, R. Sabbagh, and W. M. Milewski. 1992. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J. Infect. Dis. 166: 1066-1072.
13. Firsov, A. A., R. G. Vasilov, S. N. Vostrov, O. V. Kononenko, I. Y. Lubenko, and S. H. Zinner. 1999. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J. Antimicrob. Chemother. 43:483-490.
14. Foulds, G. 1986. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8(Suppl. 5):S503-S511.
15. Greenwood, D., K. Bidgood, and M. Turner. 1987. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin. J. Antimicrob. Chemother. 20:155-164.
16. Herwaldt, L., L. Boyken, and M. Pfaller. 1991. In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. Eur. J. Clin. Microbiol. Infect. Dis. 10:1007-1012.
17. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
18. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin. Lancet 350:1670-1673.
19. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinet. 28:143-160.
20. +-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:166-172.
21. Moreira, B., S. Boyle-Vavra, B. L. M. deJonge, and R. S. Daum. 1997. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1788-1793.
22. Mouton, J. W., and J. G. den Hollander. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
23. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayre, Pa.
24. Palmer, S. M., and M. J. Rybak. 1996. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob. Agents Chemother. 40:701-705.
25. Sanyal, D., and D. Greenwood. 1993. An electron microscope study of glycopeptide antibiotic-resistant strains of Staphylococcus epidermidis. J. Med. Microbiol. 39:204-210.
26. Sanyal, D., R. C. Johnson, R. C. George, R. Edwards, and D. Greenwood. 1993. In-vitro characteristics of glycopeptide resistant strains of Staphylococcus epidermidis isolated from patients on CAPD. J. Antimicrob. Chemother. 32:267-278.
27. Schlaes, D. M., and J. H. Schlaes. 1995. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clin. Infect. Dis. 20:1071-1073.
28. Sefton, A. F., J. P. Maskell, A. M. Rafay, A. Whiley, and J. D. Williams. 1997. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. J. Antimicrob. Chemother. 39(Suppl. B):57-62.
29. Sieradski, K., and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566.
30. Sieradski, K., and A. Tomasz. 1998. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical strains of staphylococci. Antimicrob. Agents Chemother. 42:100-107.
31. Sieradski, K., and A. Tomasz. 1998. Low-level teicoplanin resistance and heteroresistance to vancomycin. Ann. Intern. Med. 128:245.
32. Vincent, J., J. Venitz, R. Teng, B. A. Baris, S. A. Willavize, R. J. Polzer, and H. L. Friedman. 1997. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrovafloxacin. J. Antimicrob. Chemother. 39(Suppl. B): 75-80.
33. Zinner, S. H., D. Gilbert, and M. N. Dudley. 1998. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. Antimicrob. Agents Chemother. 42:72-77.